Angina Pectoris
📧 Sign up to get email alerts when something new happens for Angina Pectoris.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2017-01-31FDA Approved: NITROSTAT — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Nitrostat (nitroglycerin) from Viatris Specialty LLC, resulting in changes to the product la…
-
CLINICAL_TRIALS trial_result · 2017-01-12Clinical Trial Update: Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome [NA]
A completed clinical trial evaluated instantaneous wave-free ratio (iFR) versus fractional flow reserve (FFR) in patients with stable angina…
-
FDA approval · 2017-01-11FDA Approved: BISOPROLOL FUMARATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' Bisoprolol Fumarate (bisoprolol fumarate) via an Original Application; indicated for hypertension and …
-
FDA approval · 2016-11-30FDA Approved: METOPROLOL TARTRATE — Supplemental Application (TRUPHARMA LLC)
FDA approved a supplemental application for metoprolol tartrate submitted by TRUPHARMA LLC. This action approves the supplemental filing for…
-
FDA approval · 2016-11-25FDA Approved: METOPROLOL SUCCINATE — Original Application (Actavis Pharma, Inc.)
FDA approved the original application for metoprolol succinate, establishing a generic sustained-release formulation from Actavis Pharma, In…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Wilshire Pharmaceuticals, Inc.)
FDA approved a supplemental application for verapamil hydrochloride from Wilshire Pharmaceuticals, Inc., updating the existing NDA.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for Diltiazem hydrochloride extended-release from Oceanside Pharmaceuticals. The product is a calciu…
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals Inc)
FDA approved a supplemental application for Verapamil hydrochloride from Teva Pharmaceuticals Inc.
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (EXELA PHARMA SCIENCES, LLC)
The FDA approved a supplemental application for verapamil hydrochloride from Exela Pharma Sciences, LLC.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diltiazem hydrochloride. The approval confirms a modification to the pr…
-
FDA approval · 2016-11-18FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cardizem CD (diltiazem hydrochloride) submitted by Bausch Health US LLC.
-
FDA approval · 2016-11-08FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for MATZIM LA, a diltiazem hydrochloride product from Actavis Pharma, Inc.
-
CLINICAL_TRIALS trial_result · 2016-09-27Clinical Trial Update: Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance [Phase 4]
Phase 4 clinical trial update investigates microvascular resistance in women with chest pain who have no significant coronary artery stenosi…
-
FDA approval · 2016-09-23FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for nicardipine hydrochloride (Hikma Pharmaceuticals USA Inc.), resulting in labeling changes fo…
-
FDA approval · 2016-09-02FDA Approved: NITROGLYCERIN — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Nitroglycerin submitted by Prasco Laboratories, granting regulatory approval for this produc…
-
FDA approval · 2016-08-29FDA Approved: NITROSTAT — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Nitrostat (nitroglycerin) filed by Viatris Specialty LLC.
-
FDA approval · 2016-08-26FDA Approved: CARDENE IV — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for Cardene IV (nicardipine hydrochloride) from Baxter Healthcare Corporation, enabling an additiona…
-
FDA approval · 2016-08-25FDA Approved: NIFEDIPINE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approves Ingenus Pharmaceuticals' original application for a generic nifedipine product, enabling its marketing for hypertension and ang…
-
FDA approval · 2016-08-22FDA Approved: NITROGLYCERIN IN DEXTROSE — Supplemental Application (Baxter Healthcare Company)
FDA approved a supplemental application for NITROGLYCERIN IN DEXTROSE by Baxter Healthcare Company, indicating regulatory approval and label…
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: 6-month Intracoronary Optical Coherence Tomography (OCT) Evaluation of Three New Generation Drug Eluting Stent [NA]
Clinical trial update reporting 6-month intracoronary OCT evaluation results for three new generation drug-eluting stents in patients with r…
-
CLINICAL_TRIALS trial_result · 2016-08-15Clinical Trial Update: Cardiogenesis Transmyocardial Revascularization Registry
The Cardiogenesis Transmyocardial Revascularization trial for Class IV angina has completed and posted results on ClinicalTrials.gov in 2016…
-
CLINICAL_TRIALS trial_result · 2016-08-03Clinical Trial Update: Patient-Reported Preferences Affecting Revascularization Decisions [NA]
This clinical trial update summarizes completed findings from a Duke University study on how patient-reported preferences influence revascul…
-
CLINICAL_TRIALS trial_result · 2016-07-29Clinical Trial Update: Randomized Controlled Trial of Health Care to Elderly Patients. [NA]
A randomized controlled trial evaluating health care for elderly patients sponsored by the Norwegian University of Science and Technology ha…
-
CLINICAL_TRIALS trial_result · 2016-07-27Clinical Trial Update: Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study [Phase 4]
This Phase 4 study (SEVEN-Xience) uses optical coherence tomography to compare neointimal coverage between Xience Prime and Cypher Select st…
-
CLINICAL_TRIALS trial_result · 2016-07-27Clinical Trial Update: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis
An update on a clinical trial evaluating the effect and efficacy of the Xpedition/Alpine everolimus-eluting stent for coronary atheroscleros…